Piper Sandler downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight with an unchanged price target of $10 following Roche’s announced acquisition for $9 per share in cash and $4 per share contingent rights value.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics (NASDAQ:PSTX) Stock Skyrockets on News of Roche Holdings Acquisition
- Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz
- Poseida Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Poseida downgraded to Market Perform from Outperform at William Blair
- Poseida Therapeutics downgraded to Neutral from Buy at BTIG